QILU PHARMACEUTICAL CO., LTD. ( China (Mainland))

Qilu Pharmaceutical is engaged in developing, manufacturing and marketing generic drugs in therapeutic area of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological system, Respiratory system, Ophthalmological Diseases etc., as well as active pharmaceutical ingredients. The company has five Subsidiaries including Qilu Antibiotics Pharmaceutical Co., Ltd., Qilu Tianhe Pharmaceutical Co., Ltd., Shandong King-Phar Pharmaceutical Co., Ltd., Qilu Animal Health Products Co., Ltd. and Qilu Pharmaceutical (Hainan) Co., Ltd. It has already been certified by GMP.

Qilu Durg Research Institute is entitled as National Certificated Technology Center and National Engineering Laboratory for Bio-technology, being evaluated by relevant state bureau.They developed over 160 generics which have been launched in China and another up to 100 generics are in the pipeline, almost 50% are oncology products.

Qilu Antibiotics Pharmaceutical Co., Ltd. is specialized in Cephalosporins bulks with annual output of 1500 tons. Qilu Tianhe Pharmaceutical Co., Ltd. is engaged in synthetic APIs, not only oncology but anti-infectives including Beta-Lactam inhibitor, Tazobactam (89786-04-9). Shandong King-Phar Pharmaceutical Co.,Ltd. is engaged in producing bulk antibiotics with capacity over 15000 tons.